What is NDC 70710-1835?

70710-1835 is the product NDC for Levothyroxine Sodium, Levothyroxine sodium anhydrous 500 ug/5mL injection, powder, lyophilized, for solution, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Levothyroxine sodium anhydrous.

Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Levothyroxine Sodium?

528 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Levothyroxine Sodium NDC 70710-1835 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1835Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1835Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1835-1	70710183501	1 VIAL, SINGLE-DOSE in 1 CARTON (70710-1835-1) / 5 mL in 1 VIAL, SINGLE-DOSEMarketed from Nov 1, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Levothyroxine Sodium
Generic name (nonproprietary): levothyroxine sodium
Active ingredients: Levothyroxine sodium anhydrous — 500 ug/5mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Zydus Pharmaceuticals USA Inc.NDC labeler code 70710
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217066
Marketing start: Nov 1, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Thyroxine (Chemical structure)
Identifiers: Product ID 70710-1835_2ef84f1a-cf9a-4e93-8b2b-08bf75befd9eSPL ID 2ef84f1a-cf9a-4e93-8b2b-08bf75befd9eSPL set ID bf8a952c-f05b-4814-b55a-ed04be015269RxCUI 966219, 1115267, 1115269UNII 054I36CPMN
Pharmacologic class: l-Thyroxine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470710183501 followed by a unit qualifier and the quantity

Package 70710-1835-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 16, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Levothyroxine sodium for injection is indicated for the treatment of myxedema coma. Important Limitations of Use: The relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established. Caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. Levothyroxine sodium is an L-thyroxine product. Levothyroxine (T 4 ) sodium for injection is indicated for the treatment of myxedema coma. ( 1 ) Important Limitations of Use: The relative bioavailability of this drug has not been established. Use caution when converting patients from o…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70710-1835

What is NDC 70710-1835?: 70710-1835 is the product NDC for Levothyroxine Sodium, Levothyroxine sodium anhydrous 500 ug/5mL injection, powder, lyophilized, for solution, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Levothyroxine Sodium.
What is the active ingredient?: Levothyroxine sodium anhydrous.
Who is the labeler?: Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Levothyroxine Sodium?: 528 other product NDCs are listed under this name. See all Levothyroxine Sodium NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Levothyroxine Sodium NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Levothyroxine Sodium	Levothyroxine sodium .137 mg/1	TabletOral	Coupler LLC	67046-0972	67046-0972-03
Levothyroxine Sodium	Levothyroxine sodium .05 mg/1	TabletOral	Coupler LLC	67046-0819	67046-0819-03
Levothyroxine Sodium	Levothyroxine sodium .2 mg/1	TabletOral	Coupler LLC	67046-0387	67046-0387-03
Levothyroxine Sodium	Levothyroxine sodium .125 mg/1	TabletOral	Coupler LLC	67046-0951	67046-0951-03
Levothyroxine Sodium	Levothyroxine sodium 100 ug/1	TabletOral	Coupler LLC	67046-1679	67046-1679-03
Levothyroxine Sodium	Levothyroxine sodium .175 mg/1	TabletOral	Coupler LLC	67046-0517	67046-0517-03
Levothyroxine Sodium	Levothyroxine sodium .15 mg/1	TabletOral	Coupler LLC	67046-0515	67046-0515-03
Levothyroxine Sodium	Levothyroxine sodium .1 mg/1	TabletOral	Coupler LLC	67046-0569	67046-0569-03
Levothyroxine Sodium	Levothyroxine sodium .075 mg/1	TabletOral	Coupler LLC	67046-0801	67046-0801-03
Levothyroxine Sodium	Levothyroxine sodium .112 mg/1	TabletOral	Coupler LLC	67046-0290	67046-0290-03

All 529 Levothyroxine Sodium NDCs

Other NDCs under ANDA 217066

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217066
Product	Strength	Form · route	Labeler	Product NDC
Levothyroxine Sodium	Levothyroxine sodium anhydrous 100 ug/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Zydus Lifesciences Limited	70771-1818
Levothyroxine Sodium	Levothyroxine sodium anhydrous 100 ug/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Zydus Pharmaceuticals USA Inc.	70710-1833
Levothyroxine Sodium	Levothyroxine sodium anhydrous 200 ug/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Zydus Pharmaceuticals USA Inc.	70710-1834